UPCC 02614: The BAMM Trial: BRAF Autophagy and MEK inhibition in Metastatic Melanoma: A Phase I/II Open Label Trial of Dabrafenib Trametinib and Hydroxychloroquine in Patients with Advanced BRAF Mutant Melanoma
The main purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with advanced BRAF mutant melanoma. The study will involve mainly standard of care assessments with additional blood draw for PK/PD, tumor biopsy and occular toxicity monitoring.
- Study Identifier: 819986
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required